AKT1 and breast carcinoma: Alpelisib, targeting the PI3Kα isoform, provides meaningful benefit in PIK3CA-mutated breast cancer and represents a promising strategy in gynecologic tumors with aberrant PI3K/AKT/mTOR pathway activation.